Skip to main content
OpenTrials
Completed

NCT Number: NCT06787443

Randomized Placebo Controlled Clinical Study of an Oral Product in Subjects With Menopausal Symptoms

The objective of this study is to assess the safety and effectiveness of a dietary supplement for symptom relief in subjects with menopausal symptoms over the course of five weeks of continuous daily use.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

40 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

See Final Report

San Francisco, California, 94127, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy Females aged 40 to 65 years,
  • Self-reporting menopausal symptoms (> 5 hot flushes per day) and have been present for a minimum of previous 60 days prior to baseline visit.
  • Reporting a variable cycle length of > 7 days different from normal
  • BMI 20-40 kg/m2
  • Able to read, understand, and complete the study questionnaire and records.
  • Able to understand the study procedures.
  • Able to comply with all study requirements.
  • Written informed consent to participate in the study.
  • Willingness to actively participate in the study and to come to the scheduled visits.

Exclusion criteria

  • Pregnancy or breastfeeding.
  • Immune insufficiency
  • Women of childbearing potential including those still having a menstrual cycle on a regular basis who are not perimenopausal, menopausal or post-menopausal.
  • History of hysterectomy
  • Women on hormone replacement therapy
  • Use of systemic corticosteroids or immunosuppressant drugs.
  • Other diseases or medications that might directly interfere in the study or put the subject's health under risk.
  • Employees of the institute
  • Cardiovascular-, chronic liver-, thyroid or kidney diseases; a history of cancer; a disease or condition that could influence the participants' ability to follow the study protocol,
  • Alcohol or drug abuse,
  • Use of hormonal contraceptives within the last 3 months
  • BP ≥160/110 mmHg
  • Oophorectomy or amenorrhea > two years

Treatment and study plan

Placebo

Dietary Supplement

Eligible subjects will receive Placebo to take daily for five weeks

Dietary Supplement with Proprietary Herbal Extract Blend and GABA

Dietary Supplement

Eligible subjects will receive active product to take daily for five weeks

Primary outcomes

  1. Changes of symptom scores in Daily Dairy

    Time frame: from enrollment to the end of study at five weeks

    To assess changes in symptom scores attained from product use in subjects with menopausal symptoms, including acute effects

  2. Changes of symptom scores in Mobile Application

    Time frame: from enrollment to the end of study at five weeks

    To assess changes in symptom scores attained from product use in subjects with menopausal symptoms, including acute effects

Secondary outcomes

  1. Changes in Menopause-Specific Quality of Life (MENQOL) Scores

    Time frame: from enrollment to the end of study at five weeks

    To assess changes in mood and quality of life scores of the product compared to placebo

  2. Changes in Green Climacteric Scale (GCS) Scores

    Time frame: from enrollment to the end of study at five weeks

    To assess changes in mood scores of the product compared to placebo

  3. Changes in Perceived Stress Scale (PSS) Scores

    Time frame: from enrollment to the end of study at five weeks

    To assess changes in mood scores of the product compared to placebo

  4. Changes in Profile of Mood States (POMS) Scores

    Time frame: from enrollment to the end of study at five weeks

    To assess changes in mood scores of the product compared to placebo

  5. Changes in Pittsburgh Sleep Quality Index (PSQI) Scores

    Time frame: from enrollment to the end of study at five weeks

    To assess changes in sleep scores of the product compared to placebo

Sponsors and collaborators

Lead sponsor

Olly, PBC

Industry

Registry information

Official study title

A Randomized, Placebo Controlled Clinical Study to Examine the Clinical Benefits of an Oral Product in Subjects With Menopausal Symptoms Including Vasomotor Symptoms

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jan 22, 2025
Registry last updated
Jan 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.